

### Biovica to present at ABGs Introduce Investor Day, held in Stockholm, December 4

**Biovica will present at ABGs Introduce Investor Day, a small-cap investor seminar, held on December 4 at Haymarket in Stockholm. The company will be represented by CEO Anders Rylander in Track 2 at 10.30 CET.**

For full program and registration, see link: <http://www.introduce.se/artiklar/2018/10/introduce-investor-day---v3/>. The event will also be livestreamed at [introduce.se](http://introduce.se).

#### Contact

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35,

E-mail: [anders.rylander@biovica.com](mailto:anders.rylander@biovica.com)

#### Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE labelled and MPA registered.

Webb [www.biovica.com](http://www.biovica.com)

Contact [info@biovica.com](mailto:info@biovica.com)